C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Guidelines on Bladder Cancer
Willem Oosterlinck,Bernard Lobel,Gerhard Jakse,Per-Uno Malmström,Michael Stöckle,Cora N. Sternberg +5 more
TL;DR: Recommendations are developed for diagnosis for bladder cancer in general, treatment of superficial and infiltrative bladder cancer, and follow-up after different types of treatment modalities, such as intravesical instillations, radical cystectomy, urinary diversions, radiotherapy and chemotherapy.
Journal ArticleDOI
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Martin Bambury,Eric Voog,Jingsong Zhang,Josep M. Piulats,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Celestia S. Higano,Laurence Eliot Miles Krieger,Cora N. Sternberg,Simon Paul Watkins,Darrin Despain,Andrew Simmons,Andrea Loehr,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury,Simon Chowdhury +27 more
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
Journal ArticleDOI
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg,Robert E. Hawkins,John Wagstaff,Pamela Salman,Jozef Mardiak,Carlos H. Barrios,J. J. Zarba,Oleg Gladkov,Eunsik Lee,Cezary Szczylik,Lauren McCann,Stephen D. Rubin,Mei Chen,Ian D. Davis +13 more
TL;DR: Although no significant difference in OS was observed in this study, extensive crossover from placebo to pazopanib confounded final OS analysis and post-hoc analyses adjusting for crossover suggest OS benefit with pazobanib treatment for mRCC patients.
Journal ArticleDOI
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Bertrand Tombal,Christian Wülfing,Gero Kramer,Jean-Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Theodore,Susan Feyerabend,Carole Helissey,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Daniel Castellano,Card Investigators +19 more
TL;DR: Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen
Journal ArticleDOI
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
Janice Gabrilove,Janice Gabrilove,Ann A. Jakubowski,Ann A. Jakubowski,Howard I. Scher,Howard I. Scher,Cora N. Sternberg,Cora N. Sternberg,George Y. Wong,George Y. Wong,John Grous,John Grous,Alan Yagoda,Alan Yagoda,K. Fain,K. Fain,Malcolm A.S. Moore,Malcolm A.S. Moore,Bayard D. Clarkson,Bayard D. Clarkson,Herbert F. Oettgen,Herbert F. Oettgen,Kirby Alton,Kirby Alton,Karl Welte,Karl Welte,Lawrence M. Souza,Lawrence M. Souza +27 more
TL;DR: It is demonstrated that rhG-CSF is a potent stimulus of normal neutrophil proliferation and maturation and its administration can reduce both the hematopoietic and oral toxicity of chemotherapy.